# Abstract
Retrospective study of adamantane derivatives as neuroprotectants post-CVA

# Central NMDA Receptor Physiology
mGluR5-Ca2+ apoptosis					
- [KEGG Network: N00984](https://www.genome.jp/dbget-bin/www_bget?ne:N00984)				
- [KEGG Pathway: hsa04724](https://www.genome.jp/kegg-bin/show_pathway?hsa04724+N00984)				

Hippocampal long-tem potentiation				
- [KEGG Pathway: hsa04720](https://www.genome.jp/dbget-bin/www_bget?hsa04720)				

<p>
	<img src='img/kegg-hsa04720.png' width='350px'>
</p>

# Memantine Pharmacodynamics

https://www.drugbank.ca/drugs/DB01043

## Central activity

### Glutamateric:
- Low-affinity voltage-dependent non-competitive antagonist at glutamatergic NMDA receptors
- NMDAR antagonist with higher affinity than Mg++, ultimatly inhibits prolonged Ca++ influx
### Serotonergic:
- Non-competitive antagonist at 5-HT3 receptor, potency similar to that for the NMDA receptor
### Cholinergic:
- Non-competitive antagonist at nAChRs with potencies possibly similar to NMDA and 5-HT3 receptors
### Dopaminergic:
- Agonist at D2 receptor with equal or slightly higher affinity than NMDA receptors
### Sigmaergic:
- Agonist at Sigma-1 receptor with low Ki ~= 2.6 Î¼M (2600 nM)
- Therapeutic concentrations of memantine are most likely too low to have any sigmaergic effect, as a typical therapeutic dose is 20mg.
- Excessive doses of memantine (e.g. recreational use) may indeed activate Sigma-1
	- https://erowid.org/experiences/subs/exp_Pharms_Memantine.shtml

## ADME Kinetics

## Cytochrome P450 2B6

https://www.drugbank.ca/drugs/DB01043

Micuda S, Mundlova L, Anzenbacherova E, Anzenbacher P, Chladek J, Fuksa L, Martinkova J: Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol. 2004 Oct;60(8):583-9. doi: 10.1007/s00228-004-0825-1. Epub 2004 Sep 16. [PubMed:15378224]


A cytochrome P450 monooxygenase ([CYP2B6](https://www.uniprot.org/uniprot/P20813)) involved in the metabolism of endocannabinoids and steroids (PubMed:21289075, PubMed:12865317). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:21289075). Hydroxylates steroid hormones, including testosterone at C-16 and estrogens at C-2 (PubMed:21289075, PubMed:12865317). Plays a role in the oxidative metabolism of xenobiotics, including plant lipids and drugs (PubMed:11695850, PubMed:22909231). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850).

## Unknown NMDAR/GluR drug interactions
- Statins
- ACEi/ARB
- Ca++ channel blockers 
- Alpha-2 antagonists (precedex, clonidine)
- Octeotide
- Epoprostenol

# References

Dugbank 
[DB01043](https://www.drugbank.ca/drugs/DB01043)

Human Metabolome Database
[HMDB0015177](http://www.hmdb.ca/metabolites/HMDB0015177)

KEGG Drug
[D08174](http://www.genome.jp/dbget-bin/www_bget?drug:D08174)

KEGG Compound
[C13736](http://www.genome.jp/dbget-bin/www_bget?cpd:C13736)

PubChem Compound
[4054](http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4054)

PubChem Substance
[46506702](http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506702)

ChemSpider
[3914](http://www.chemspider.com/Chemical-Structure.3914.html)

BindingDB
[50062599](http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50062599)

RxNav
[6719](https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=6719)

ChEBI
[64312](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=64312)

ChEMBL
[CHEMBL807](http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL807)

Therapeutic Targets Database
[DAP000493](http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000493)

PharmGKB
[PA10364](http://www.pharmgkb.org/drug/PA10364)


